Nike’s turnaround is stalling, and its Converse brand is a big reason why

Converse sales fell 28% in Nike’s most recent quarter, after declining from a 2023 peak of $2.43 billion to $1.17 billion last fiscal year; continued declines could push annual sales below $1 billion for the first time since 2010. Analysts attribute the slump to weak innovation and reliance on Chuck Taylor, and one BNP Paribas analyst said Nike could sell the brand. Nike CEO Elliott Hill says he is focused on restoring Converse’s financial health, with an update expected at Nike’s investor day next month.

Analysis

Converse is more important as a credibility signal than as a direct revenue shock: its small share of Nike’s sales limits the obvious top-line hit, but its disproportionate contribution to the latest decline exposes the difficulty of repairing the portfolio. Without segment margin and inventory data, the earnings drag cannot be quantified; the larger risk is that continued weakness reinforces doubts about Nike’s broader product and execution reset, weighing on the recovery multiple.

The next-month investor-day update is the near-term catalyst. Generic reassurance would leave investors unable to assess whether Nike can refresh the franchise, reduce dependence on a single silhouette, or improve sell-through without discounting. A sale could simplify management focus and surface value, but may also crystallize a weak-cycle price and remove turnaround optionality. Treat any disposal speculation as optionality, not a base case.

Competitive read-through is selective. Adidas’s successful variation of heritage styles supports the case that product iteration can revive classics; it is not proof Converse can reproduce that outcome. On Holding and Deckers’ HOKA are plausible alternatives for some lifestyle-footwear spending, while V.F. Corporation’s Vans weakness argues against assuming all classic sneaker brands benefit from Converse’s decline. The contrarian point: the sales slump is severe, but at this revenue weight it is not by itself a compelling short thesis on Nike; the market may be over-attributing the brand’s specific problem to consolidated earnings while underweighting its value as evidence about execution.

Key Decisions for Investors

• Do not initiate a standalone NKE short solely on Converse. Before the investor day, verify Converse sell-through, inventory, discounting, and segment profitability; these are needed to translate reported sales pressure into earnings impact.
• Use the investor day as a decision point: if Nike offers no measurable product and financial-health milestones, consider a modest relative-value short NKE / long adidas (ADS), with risk capped around the event. The thesis is relative execution credibility, not a claim that Adidas directly captures Converse sales.
• Falsify the bearish read-through if Nike provides credible evidence of improving Converse sell-through and reduced reliance on Chuck Taylor, or if consolidated guidance and other key brand trends improve despite Converse weakness. Conversely, further deterioration alongside weaker Nike guidance would strengthen the execution-risk thesis.
• Keep a conditional watch on a Converse divestiture. Assess proceeds, retained liabilities, and whether management commits the freed-up resources to core operations before treating a sale as value-accretive; absent those details, do not price in a disposal premium.